Q2 Earnings: Regeneron and Cigna Outperform Expectations
- August 03rd, 2023
- 362 views
Shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) surged over 5% in pre-market trading following an impressive second quarter 2023 earnings report. The company exceeded expectations, reporting adjusted earnings per share (EPS) of $10.24 and revenues of $3.16 billion, surpassing the consensus estimates of $9.84 on revenues of $3.01 billion.
In pre-market, $REGN was trading at $778.10, reflecting a gain of $45.98 (+6.28%).
In a separate development, The Cigna Group (NYSE: CI) unveiled its Q2 2023 financial results, with adjusted EPS of $6.13 and revenues of $48.62 billion, outperforming the consensus estimate of $6.02 on revenue of $47.31 billion.
Looking ahead, the company provided an optimistic outlook for full-year 2023 adjusted EPS, targeting at least $24.70, surpassing the consensus projection of $24.69.
$CI was trading at $299.80 in pre-market, up $0.40 (+0.13%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login